Preview

Антибиотики и Химиотерапия

Расширенный поиск
Доступ открыт Открытый доступ  Доступ закрыт Доступ платный или только для Подписчиков

Левофлоксацин. Целесообразность высокодозовых режимов при инфекциях нижних дыхательных путей

Полный текст:

Об авторах

И. А. Гучев
421 Военный госпиталь Московского военного округа Министерства Обороны РФ, Смоленск
Россия


Е. В. Мелехина
Смоленская государственная медицинская академия
Россия


О. В. Юденич
421 Военный госпиталь Московского военного округа Министерства Обороны РФ, Смоленск
Россия


Список литературы

1. Davis R., Bryson H.M. Levofloxacin. A review of its antibacterial activity, pharmacokinetics and therapeutic efficacy. Drugs 1994; 47: 677-700.

2. Nomura K., Fujimoto Y., Morimoto Y. et al. Population pharmacokinetics of levofloxacin as prophylaxis for febrile neutropenia. Internal medicine (Tokyo, Japan) 2008; 47: 375-378.

3. Nicolle L., Duckworth H., Sitar D. et al. Pharmacokinetics/pharmacodynamics of levofloxacin 750 mg once daily in young women with acute uncomplicated pyelonephritis. Intern J Antimicrob Agents 2008; 31: 287-289.

4. Oberdorfer K., Swoboda S., Hamann A. et al. Tissue and serum levofloxacin concentrations in diabetic foot infection patients. J Antimicrob Chemother 2004; 54: 836-839.

5. Trampuz A., Wenk M., Rajacic Z., Zimmerli W. Pharmacokinetics and pharmacodynamics of levofloxacin against Streptococcus pneumoniae and Staphylococcus aureus in human skin blister fluid. Antimicrob Agents Chemother 2000; 44: 1352-1355.

6. Garraffo R., Lavrut T., Durant J. et al. In vivo comparative pharmacokinetics and pharmacodynamics of moxifloxacin and levofloxacin in human neutrophils. Clin Drug Investig 2005; 25: 643-650.

7. Peloquin C.A., Hadad D.J., Molino L.P. et al. Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis. Antimicrob Agents Chemother 2008; 52: 852-857.

8. Kiser T.H., Hoody D.W., Obritsch M.D. et al. Levofloxacin pharmacokinetics and pharmacodynamics in patients with severe burn injury. Ibid 2006; 50: 1937-1945.

9. Zeitlinger M.A., Traunmuller F., Abrahim A. et al. A pilot study testing whether concentrations of levofloxacin in interstitial space fluid of soft tissues may serve as a surrogate for predicting its pharmacokinetics in lung. Intern J Antimicrob Agents 2007; 29: 44-50.

10. Wagenlehner F.M., Kinzig-Schippers M., Sorgel F. et al. Concentrations in plasma, urinary excretion and bactericidal activity of levofloxacin (500 mg) versus ciprofloxacin (500 mg) in healthy volunteers receiving a single oral dose. Ibid 2006; 28: 551-559.

11. Overholser B.R., Kays M.B., Lagvankar S. et al. Pharmacokinetics of intravenously administered levofloxacin in men and women. Pharmacotherapy 2005; 25: 1310-1318.

12. Almeida S., Filipe A., Almeida A., Wong H. et al. Comparative bioavailability of two formulations of levofloxacin and effect of sex on bioequivalence analysis. Data from a randomised, 2х2 crossover trial in healthy volunteers. Arzneimittel-Forschung 2005; 55: 414-419.

13. Noreddin A.M., Marras T.K., Sanders K. et al. Pharmacodynamic target attainment analysis against Streptococcus pneumoniae using levofloxacin 500 mg, 750 mg and 1000 mg once daily in plasma (P) and epithelial lining fluid (ELF) of hospitalized patients with community-acquired pneumonia (CAP). Intern J Antimicrob Agents 2004; 24: 479-484.

14. Noreddin A.M., Hoban D.J., Zhanel G.G. Comparison of gatifloxacin and levofloxacin administered at various dosing regimens to hospitalised patients with community-acquired pneumonia: pharmacodynamic target attainment study using North American surveillance data for Streptococcus pneumoniae. Intern J Antimicrob Agents 2005; 26: 120-125.

15. Wagenlehner F.M., Kinzig-Schippers M., Tischmeyer U. et al. Pharmacokinetics of ciprofloxacin XR (1000 mg) versus levofloxacin (500 mg) in plasma and urine of male and female healthy volunteers receiving a single oral dose. Ibid 2006; 27: 7-14.

16. Hurst M., Lamb H.M., Scott L.J., Figgitt D.P. Levofloxacin: an updated review of its use in the treatment of bacterial infections. Drugs 2002; 62: 2127-2167.

17. Drusano G.L., Johnson D.E., Rosen M., Standiford H.C. Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis. Antimicrob Agents Chemotherapy 1993; 37: 483-490.

18. Preston S.L., Drusano G.L., Berman A.L. et al. Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. JAMA 1998; 279: 125-129.

19. Scaglione F., Mouton J.W., Mattina R., Fraschini F. Pharmacodynamics of levofloxacin and ciprofloxacin in a murine pneumonia model: peak concentration/MIC versus area under the curve/MIC ratios. Antimicrob Agents Chemother 2003; 47: 2749-2755.

20. Odenholt I., Cars O. Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli: simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model. J Antimicrob Chemother 2006; 58: 960-965.

21. Deryke C.A., Du X., Nicolau D.P. Evaluation of bacterial kill when modelling the bronchopulmonary pharmacokinetic profile of moxifloxacin and levofloxacin against parC-containing isolates of Streptococcus pneumoniae. J Antimicrob Chemother 2006; 58: 601-609.

22. Ambrose P.G., Bhavnani S.M., Rubino C.M. et al. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: It's Not Just for Mice Anymore. Clin Infect Dis 2007; 44: 79-86.

23. Booker B.M., Smith P.F., Forrest A. et al. Application of an in vitro infection model and simulation for reevaluation of fluoroquinolone breakpoints for Salmonella enterica serotype typhi. Antimicrobial agents and chemotherapy 2005; 49: 1775-1781.

24. Bhavnani S.M., Forrest A., Hammel J.P. et al. Pharmacokinetics-pharmacodynamics of quinolones against Streptococcus pneumoniae in patients with community-acquired pneumonia. Diagn Microbiol Infect Dis 2008; 62: 99-101.

25. Drusano G.L., Preston S.L., Fowler C. et al. Relationship between fluoroquinolone area under the curve: minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia. J Infect Dis 2004; 189: 1590-1597.

26. LaPlante K.L., Rybak M.J., Tsuji B. et al. Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemi-floxacin, levofloxacin, and moxifloxacin. Antimicrob Agents Chemother 2007; 51: 1315-1320.

27. Brown S.D., Rybak M.J. Antimicrobial susceptibility of Streptococcus pneumoniae, Streptococcus pyogenes and Haemophilus influenzae collected from patients across the USA, in 2001-2002, as part of the PROTEKT US study. J Antimicrob Chemother 2004; 54: i7-15.

28. Jenkins S.G., Brown S.D., Farrell D.J. Trends in antibacterial resistance among Streptococcus pneumoniae isolated in the USA: update from PROTEKT US Years 1-4. Annals Clin Microbiol Antimicrob 2008; 7: 1.

29. Jacobs E., Dalhoff A., Korfmann G. Susceptibility patterns of bacterial isolates from hospitalised patients with respiratory tract infections (MOXIAKTIV Study). Intern J Antimicrob Agents 2008.

30. Davies T.A., Yee Y.C., Goldschmidt R. et al. Infrequent occurrence of single mutations in topoisomerase IV and DNA gyrase genes among US levofloxacin-susceptible clinical isolates of Streptococcus pneumoniae from nine institutions (1999-2003). J Antimicrob Chemother 2006; 57: 437-442.

31. Sohma M., Yokozawa I., Kaneko S., Satake S. Epidemiological study of levofloxacin-resistant Streptococcus pneumoniae isolated from 2003 through 2006 in Japan. Kansenshogaku zasshi 2009; 83: 113-119.

32. Козлов P.С., Сивая О.В., Шпынев К.В. и др. Антибиотикорезистентность Streptococcus pneumoniae в России в 1999-2005 гг.: результаты многоцентровых проспективных исследований ПеГАС-I и ПеГАС-II. Клин. микробиол. антимикроб. химиотер. 2006; 8: 33-47.

33. Hsieh Y.C., Chang L.Y., Huang Y.C. et al. Circulation of international clones of levofloxacin non-susceptible Streptococcus pneumoniae in Taiwan. Clin Microbiol Infect 2009.

34. Sahm D.F., Brown N.P., Thornsberry C., Jones M.E. Antimicrobial susceptibility profiles among common respiratory tract pathogens: a GLOBAL perspective. Postgraduate Med 2008; 120: 16-24.

35. Srifuengfung S., Tribuddharat C., Champreeda P. et al. Antimicrobial susceptibility of Streptococcus pneumoniae isolated from patients with respiratory tract infections in Thailand. The Southeast Asian J Tropic Med 2008; 39: 461-466.

36. Thornsberry C., Brown N.P., Draghi D.C. et al. Antimicrobial activity among multidrug-resistant Streptococcus pneumoniae isolated in the United States, 2001-2005. Postgraduate medicine 2008; 120: 32-38.

37. Farrell D.J., Couturier C., Hryniewicz W. Distribution and antibacterial susceptibility of macrolide resistance genotypes in Streptococcus pneumoniae: PROTEKT Year 5 (2003-2004). Intern J Antimicrob Agents. 2008.

38. Defife R., Scheetz M.H., Feinglass J.M. et al. Effect of differences in MIC values on clinical outcomes in patients with bloodstream infections caused by gram-negative organisms treated with levofloxacin. Antimicrob Agents Chemother 2009; 53: 1074-1079.

39. Mouton J.W. Impact of pharmacodynamics on breakpoint selection for susceptibility testing. Infectious Disease Clinics of North America 2003; 17: 579-598.

40. Frei C.R., Wiederhold N.P., Burgess D.S. Antimicrobial breakpoints for gram-negative aerobic bacteria based on pharmacokinetic-pharmacodynamic models with Monte Carlo simulation. J Antimicrob Chemother 2008; 61: 621-628.

41. Jacobs E., Dalhoff A., Korfmann G. Susceptibility patterns of bacterial isolates from hospitalized patients with respiratory tract infections (MOXIAKTIV Study). Intern J Antimicrob Agents 2009; 33: 52-57.

42. Bastida T., Perez-Vazquez M., Campos J. et al. Levofloxacin treatment failure in Haemophilus influenzae pneumonia. Emerg Infect Dis 2003; 9: 1475-1478.

43. Perez-Vazquez M., Roman F., Aracil B., Canton R., Campos J. Laboratory detection of Haemophilus influenzae with decreased susceptibility to nalidixic acid, ciprofloxacin, levofloxacin, and moxifloxacin due to gyrA and parC mutations. J Clin Microbiol 2004; 42: 1185-1191.

44. Alou L., Aguilar L., Sevillano D. et al. Levofloxacin vs. azithromycin pharmacodynamic activity against S.pneumoniae and H.influenzae with decreased susceptibility to amoxicillin/clavulanic acid. J Chemotherapy (Florence, Italy) 2007; 19: 670-672.

45. Gracia M., Diaz C., Coronel P. et al. Antimicrobial susceptibility of Streptococcus pyogenes in Central, Eastern, and Baltic European Countries, 2005 to 2006: the cefditoren surveillance program. Diagn Microbiol Infect Dis 2009; 64: 52-56.

46. Jones R.N., Sader H.S., Fritsche T.R., Pottumarthy S. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004). Ibid 2007; 57: 109-116.

47. Seral C., Suarez L., Rubio-Calvo C. et al. In vitro activity of cefditoren and other antimicrobial agents against 288 Streptococcus pneumoniae and 220 Haemophilus influenzae clinical strains isolated in Zaragoza, Spain. Diagn Microbiol Infect Dis 2008; 62: 210-215.

48. European Committee on Antimicrobial Susceptibility Testing (EUCAST). Clinical breakpoints. http://www.srga.org/eucastwt/MICTAB [accessed 10 February 2010].

49. Дехнич А.В., Эйдельштейн И.A., Нарезкина А.Д. и др. Эпидемиология антибиотикорезистентности нозокомиальных штаммов Staphylococcus aureus в России: результаты многоцентрового исследования. Клин. микробиол. антимикроб. химиотер. 2002; 4: 325-336.

50. Fritsche T.R., Sader H.S., Jones R.N. Potency and spectrum of garenoxacin tested against an international collection of skin and soft tissue infection pathogens: report from the SENTRY antimicrobial surveillance program (1999-2004). Diagn Microbiol Infect Dis 2007; 58: 19-26.

51. Goff D.A., Dowzicky M.J. Prevalence and regional variation in methicillin-resistant Staphylococcus aureus (MRSA) in the USA and comparative in vitro activity of tigecycline, a glycylcycline antimicrobial. J Med Microbiol 2007; 56: 1189-1193.

52. Huband M.D., Cohen M.A., Zurack M. et al. In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groups. Antimicrob Agents Chemother 2007; 51: 1191-1201.

53. Sader H.S., Watters A.A., Fritsche T.R., Jones R.N. Activity of daptomycin and selected antimicrobial agents tested against Staphylococcus aureus from patients with bloodstream infections hospitalized in European medical centers. J Chemotherapy (Florence, Italy) 2008; 20: 28-32.

54. Murillo O., Pachon M.E., Euba G. et al. High doses of levofloxacin vs moxifloxacin against staphylococcal experimental foreign-body infection: the effect of higher MIC-related pharmacokinetic parameters on efficacy. J Infect 2009; 58: 220-226.

55. Guss J., Doghramji L., Edelstein P.H., Chiu A.G. Fluoroquinolone-resistant Pseudomonas aeruginosa in chronic rhinosinusitis. ORL; J Oto-rhino-laryngol Related Special 2009; 71: 263-267.

56. Lanzafame A., Bonfiglio G., Santini L., Mattina R. In vitro activity of levofloxacin against recent Gram-negative nosocomial pathogens. Chemotherapy 2005; 51: 44-50.

57. Tennenberg A.M., Davis N.B., Wu S.C., Kahn J. Pneumonia due to Pseudomonas aeruginosa: the levofloxacin clinical trials experience. Curr Med Res Opin 2006; 22: 843-850.

58. Jones R.N., Sader H.S., Beach M.L. Contemporary in vitro spectrum of activity summary for antimicrobial agents tested against 18569 strains non-fermentative gram-negative bacilli isolated in the SENTRY antimicrobial surveillance program (1997-2001). Intern J Antimicrob Agents 2003; 22: 551-556.

59. Howard W., Biedenbach D.J., Jones R.N. Comparative antimicrobial spectrum and activity of the desfluoroquinolone BMS284756 (T-3811) tested against non-fermentative Gram-negative bacilli. Clin Microbiol Infect 2002; 8: 340-344.

60. Paterson D.L., Adams J., Doi Y. In vitro activity of PZ-601 (SMP-601), a novel carbapenem, against extended-spectrum beta-lactamase producing organisms [Poster No. F1-346]. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2007 Sep 17-20; Chicago (IL).

61. Rossi F., Baquero F., Hsueh P.R. et al. In vitro susceptibilities of aerobic and facultatively anaerobic gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: 2004 results from SMART (Study for Monitoring Antimicrobial Resistance Trends). J Antimicrob Chemother 2006; 58: 205-210.

62. Jonas D., Engels I., Friedhoff C., Spitzmuller B. et al. Efficacy of moxifloxacin, trovafloxacin, clinafloxacin and levofloxacin against intracellular Legionella pneumophila. Ibid 2001; 47: 147-152.

63. Zhanel G.G., DeCorby M., Nichol K.A. et al. Antimicrobial susceptibility of 3931 organisms isolated from intensive care units in Canada: Canadian National Intensive Care Unit Study, 2005/2006. Diagn Microbiol Infect Dis 2008; 62: 67-80.

64. Zhang J., Yu J.C., Shi Y.G. et al. Study of pharmacokinetics/pharmacodynamics of levofloxacin. Zhonghua Yi Xue Za Zhi 2005; 85: 1926-1932.

65. Yamaguchi K., Ohno A., Ishii Y. et al. In vitro susceptibilites to levofloxacin and various antibacterial agents of 18,639 clinical isolates obtained from 77 centers in 2004. Japan J Antibiot 2006; 59: 428-451.

66. Blondeau J.M., Hansen G., Metzler K.L. et al. In vitro susceptibility of 4903 bacterial isolates to gemifloxacin - an advanced fluoroquinolone. Intern J Antimicrob Agents 2003; 22: 147-154.

67. Ishida H., Ishida Y., Kurosaka Y. et al. In vitro and in vivo activities of levofloxacin against biofilm-producing Pseudomonas aeruginosa. Antimicrob Agents Chemother 1998; 42: 1641-1645.

68. Passerini de Rossi B., Garcia C., Calenda M. et al. Activity oflevofloxacin and ciprofloxacin on biofilms and planktonic cells of Stenotrophomonas maltophilia isolates from patients with device-associated infections. Intern J Antimicrob Agents 2009; 34: 260-264.

69. Kaji C., Watanabe K., Apicella M.A., Watanabe H. Antimicrobial effect of fluoroquinolones for the eradication of nontypeable Haemophilus influenzae isolates within biofilms. Tohoku J Exper Med 2008; 214: 121-128

70. De Vecchi E., Nicola L., Ossola F., Drago L. In vitro selection of resistance in Streptococcus pneumoniae at in vivo fluoroquinolone concentrations. J Antimicrob Chemother 2009; 63: 721-727.

71. Endimiani A., Brigante G., Bettaccini A.A. et al. Failure of levofloxacin treatment in community-acquired pneumococcal pneumonia. BMC Infect Dis 2005; 5: 106.

72. Lister P.D. Pharmacodynamics of levofloxacin against characterized ciprofloxacin-resistant Streptococcus pneumoniae. Postgraduate Med 2008; 120: 46-52.

73. Schafer J., Hovde L.B., Simonson D., Rotschafer J.C. In vitro pharmacodynamics of moxifloxacin versus levofloxacin against 4 strains of Streptococcus pneumoniae: 1 wild type, 2 first-step parC mutants, and 1 pump mutant. Diagn Microbiol Infect Dis 2008; 60: 155-161.

74. Conte J.E., Jr., Golden J.A., McIver M., Zurlinden E. Intrapulmonary pharmacokinetics and pharmacodynamics of high-dose levofloxacin in healthy volunteer subjects. Intern J Antimicrob Agents 2006; 28: 114-121.

75. Louie A., Fregeau C., Liu W. et al. Pharmacodynamics of levofloxacin in a murine pneumonia model of Pseudomonas aeruginosa infection: determination of epithelial lining fluid targets. Antimicrob Agents Chemother 2009; 53: 3325-3330.

76. Conte J.E., Golden J.A., McIver M. et al. Intrapulmonary pharmacodynamics of high-dose levofloxacin in subjects with chronic bronchitis or chronic obstructive pulmonary disease. Intern J Antimicrob Agents 2007; 30: 422-427.

77. Kitamura A., Hoshino K., Kimura Y. et al. Contribution of the C-8 substituent of DU-6859a, a new potent fluoroquinolone, to its activity against DNA gyrase mutants of Pseudomonas aeruginosa. Antimicrob Agents Chemother 1995; 39: 1467-1471.

78. Dalhoff A. Comparative in vitro and in vivo activity of the C-8 methoxy quinolone moxifloxacin and the C-8 chlorine quinolone BAY y 3118. Clin Infect Dis 2001: S16-S22.

79. Zhao X., Drlica K. Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies. Ibid 2001; 33: S147-S56.

80. Mascellino M.T., Delogu G., Pelaia M.R. et al. Reduced bactericidal activity against Staphylococcus aureus and Pseudomonas aeruginosa of blood neutrophils from patients with early adult respiratory distress syndrome. J Med Microbiol 2001; 50: 49-54.

81. Delogu G., Iona E., Amati F. «Killing» of Pseudomonas aeruginosa isolated from patients with critical post-operative complications. Effects of various antibiotics. Annali italiani di chirurgia 1997; 68: 219-224.

82. Pruul H., McDonald P.J. Lomefloxacin-induced modification of the kinetics of growth of gram-negative bacteria and susceptibility to phagocytic killing by human neutrophils. J Antimicrob Chemother 1990; 25: 91-101.

83. Scorneaux B., Ouadrhiri Y., Anzalone G., Tulkens P.M. Effect of recombinant human gamma-interferon on intracellular activities of antibiotics against Listeria monocytogenes in the human macrophage cell line THP-1. Antimicrob Agents Chemother (Bethesda) 1996; 40: 1225-1230.

84. Huang H.C., Shieh C.C., Yu W.L. et al. Comparing the protective effects of ciprofloxacin, moxifloxacin and levofloxacin in mice with lipopolysaccharide-induced acute lung injuries. Respirology (Carlton, Vic) 2008; 13: 47-52.

85. Ogino H., Fujii M., Ono M., Maezawa K. et al. In vivo and in vitro effects of fluoroquinolones on lipopolysaccharide-induced pro-inflammatory cytokine production. J Infect Chemother 2009; 15: 168-1673.

86. Calbo E., Alsina M., Rodriguez-Carballeira M. et al. Systemic expression of cytokine production in patients with severe pneumococcal pneumonia: effects of treatment with a beta-lactam versus a fluoroquinolone. Antimicrobial Agents Chemother 2008; 52: 2395-2402.

87. Pai M.P., Allen S.E., Amsden G.W. Altered steady state pharmacokinetics of levofloxacin in adult cystic fibrosis patients receiving calcium carbonate. J Cyst Fibros 2006; 5: 153-157.

88. Stergiopoulou T., Meletiadis J., Sein T. et al. Comparative pharmacodynamic interaction analysis between ciprofloxacin, moxifloxacin and levofloxacin and antifungal agents against Candida albicans and Aspergillusfumigatus. J Antimicrob Chemother 2009; 63: 343-348.

89. Elkhatib W.F., Haynes V.L., Noreddin A.M. Microbiological appraisal of levofloxacin activity against Pseudomonas aeruginosa biofilm in combination with different calcium chanel blockers in vitro. J Chemotherapy (Florence, Italy) 2009; 21: 135-143.

90. Chidiac C. Acute community-acquired pneumonia. A review of clinical trials. Med Mal Infect 2006; 36: 650-666.

91. Dryden M., Hand K., Davey P. Antibiotics for community-acquired pneumonia. J Antimicrob Chemother 2009; 64: 1123-1125.

92. Lim W.S., Baudouin S.V., George R.C. et al. British Thoracic Society guidelines for the management of community-acquired pneumonia in adults: update 2009. Thorax 2009; 64: iii1-iii55.

93. Robenshtok E., Shefet D., Gafter-Gvili A. et al. Empiric antibiotic coverage of atypical pathogens for community-acquired pneumonia in hospitalized adults. Cochrane database of systematic reviews (Online) 2008: CD004418.

94. Shefet D., Robenshtock E., Paul M., Leibovici L. Empiric antibiotic coverage of atypical pathogens for community-acquired pneumonia in hospitalized adults. Ibid (Online) 2005: CD004418.

95. Mills G.D., Oehley M.R., Arrol B. Effectiveness of beta lactam antibiotics compared with antibiotics active against atypical pathogens in non-severe community-acquired pneumonia: meta-analysis. BMJ (Clinical research ed) 2005; 330: 456.

96. Soriano F., Cafini F., Aguilar L. et al. Breakthrough in penicillin resistance? Streptococcus pneumoniae isolates with penicillin/cefotaxime MICs of 16 mg/l and their genotypic and geographical relatedness. J Antimicrob Chemother 2008.

97. Torres A., Garau J., Arvis P. et al. Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study - a randomized clinical trial. Clin Infect Dis 2008; 46: 1499-1509.

98. Marti-Carvajal A., Salanti G., Cardona A.F. Human recombinant activated protein C for severe sepsis. Cochrane database of systematic reviews (Online) 2008: CD004388.

99. Confalonieri M., Urbino R., Potena A. et al. Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study. American J Respir Critic Car Med 2005; 171: 242-248.

100. Shorr A.F., Zadeikis N., Jackson W.L. et al. Levofloxacin for treatment of ventilator-associated pneumonia: a subgroup analysis from a randomized trial. Clin Infect Dis 2005; 40: Suppl 2: S123-129.

101. Shorr A.F., Susla G.B., Kollef M.H. Quinolones for treatment of nosocomial pneumonia: a meta-analysis. Ibid 2005; 40: Suppl 2: S115-122.

102. Vardakas K.Z., Siempos I.I., Grammatikos A. et al. Respiratory fluoroquinolones for the treatment of community-acquired pneumonia: a metaanalysis of randomized controlled trials. CMAJ 2008; 179: 1269-1277.

103. Bru J.P., Leophonte P., Veyssier P. Levofloxacine for the treatment of pneumococcal pneumonia: results of a meta-analysis. Rev Pneumol Clinique 2003; 59: 348-356.

104. Peterson J., Yektashenas B., Fisher A.C. Levofloxacin for the treatment of pneumonia caused by Streptococcus pneumoniae including multidrug-resistant strains: pooled analysis. Curr Med Res Opin 2009.

105. Lodise T.P., Kwa A., Cosler L. et al. Comparison of {beta}-lactam and macrolide combination therapy versus fluoroquinolone monotherapy in hospitalized veterans affairs patients with community-acquired pneumonia. Antimicrob Agents Chemother 2007; 51: 3977-3982.

106. Mortensen E.M., Restrepo M.I., Anzueto A., Pugh J. The impact of empiric antimicrobial therapy with a beta-lactam and fluoroquinolone on mortality for patients hospitalized with severe pneumonia. Critical care (London, England) 2005; 10: R8.

107. Dunbar L.M., Wunderink R.G., Habib M.P. et al. High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm. Clin Infect Dis 2003; 37: 752-760.

108. Dunbar L.M., Khashab M.M., Kahn J.B. et al. Efficacy of 750-mg, 5-day levofloxacin in the treatment of community-acquired pneumonia caused by atypical pathogens. Curr Med Res Opin 2004; 20: 555-563.

109. Shorr A.F., Khashab M.M., Xiang J.X. et al. Levofloxacin 750-mg for 5 days for the treatment of hospitalized Fine Risk Class III/IV community-acquired pneumonia patients. Respir Med 2006; 100: 2129-2136.

110. Shorr A.F., Zadeikis N., Xiang J.X. et al. A multicenter, randomized, double-blind, retrospective comparison of 5- and 10-day regimens of levofloxacin in a subgroup of patients aged > or =65 years with community-acquired pneumonia. Clin Ther 2005; 27: 1251-1259.

111. Tanaseanu C., Milutinovic S., Calistru P.I. et al. Efficacy and safety of tigecycline versus levofloxacin for community-acquired pneumonia. BMC Pulmon Med 2009; 9: 44.

112. Anzueto A., Niederman M.S., Pearle J. et al. Community-acquired pneumonia recovery in the elderly (CAPRIE): efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy. Clin Infect Dis 2006; 42: 73-81.

113. D'Ignazio J., Camere M.A., Lewis D.E. et al. Novel, single-dose microsphere formulation of azithromycin versus 7-day levofloxacin therapy for treatment of mild to moderate community-acquired pneumonia in adults. Antimicrob Agents Chemother 2005; 49: 4035-4041.

114. Kalbermatter V., Bagilet D., Diab M., Javkin E. Oral levofloxacin versus intravenous ceftriaxone and amoxicillin/clavulanic acid in the treatment of community-acquired pneumonia that requires hospitalization. Med Clin 2000; 115: 561-563.

115. Ye X., Sikirica V., Schein J.R. et al. Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: A retrospective claims database analysis. Clin Ther 2008; 30: 358-371.

116. Carlavilla A.B., Lopez-Medrano F., Chaves F. et al. Failure of levofloxacin therapy in two cases of community-acquired pneumonia caused by fluoroquinolone-resistant Streptococcus pneumoniae and complicated with empyema. Enfermed Infec Microbiol Clin 2005; 23: 270-273.

117. de Cueto M., Rodriguez J.M., Soriano M.J. et al. Fatal levofloxacin failure in treatment of a bacteriemic patient infected with Streptococcus pneumoniae with a preexisting parC mutation. J Clin Microbiol 2008; 46: 1558-1560.

118. Empey P.E., Jennings H.R., Thornton A.C. et al. Levofloxacin failure in a patient with pneumococcal pneumonia. Ann Pharmacother 2001; 35: 687-690.

119. Fuller J.D., Low D.E. A review of Streptococcus pneumoniae infection treatment failures associated with fluoroquinolone resistance. Clin Infect Dis 2005; 41: 118-121.

120. Kays M.B., Smith D.W., Wack M.E., Denys G.A. Levofloxacin treatment failure in a patient with fluoroquinolone-resistant Streptococcus pneumoniae pneumonia. Pharmacotherapy 2002; 22: 395-399.

121. Sun H.K., Du X., Deryke C.A. et al. parE mutations in Streptococcus pneumoniae may reduce bactericidal activity of respiratory fluoroquinolones. Intern J Antimicrob Agents 2007; 29: 230-232.

122. Lee S.Y., Fan H.W., Sutherland C. et al. Antibacterial effects of moxifloxacin and levofloxacin simulating epithelial lining fluid concentrations against community-acquired methicillin-resistant Staphylococcus aureus. Drugs in R&D 2007; 8: 69-77.

123. Schein J., Janagap-Benson C., Grant R. et al. A comparison of levofloxacin and moxifloxacin use in hospitalized community-acquired pneumonia (CAP) patients in the US: focus on length of stay. Curr Med Res Opin 2008; 24: 895-906.

124. Frei C.R., Jaso T.C., Mortensen E.M. et al. Medical resource utilization among community-acquired pneumonia patients initially treated with levofloxacin 750 mg daily versus ceftriaxone 1000 mg plus azithromycin 500 mg daily: a US-based study. Ibid 2009; 25: 859-868.

125. Friedman H., Song X., Crespi S., Navaratnam P. Comparative analysis of length of stay, total costs, and treatment success between intravenous moxifloxacin 400 mg and levofloxacin 750 mg among hospitalized patients with community-acquired pneumonia. Value Health 2009.

126. Raut M., Schein J., Mody S. et al. Estimating the economic impact of a half-day reduction in length of hospital stay among patients with community-acquired pneumonia in the US. Curr Med Res Opin 2009.

127. Charles P.G., Whitby M., Fuller A.J. et al. The etiology of community-acquired pneumonia in Australia: why penicillin plus doxycycline or a macrolide is the most appropriate therapy. Clin Infect Dis 2008; 46: 1513-1521.

128. Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. Chest 2000; 117: 398S-401S.

129. Alvarez-Sala J.L., Kardos P., Martinez-Beltran J. et al. Clinical and bacteriological efficacy in treatment of acute exacerbations of chronic bronchitis with cefditoren-pivoxil versus cefuroxime-axetil. Antimicrob Agents Chemother 2006; 50: 1762-1767.

130. Ball P. Epidemiology and treatment of chronic bronchitis and its exacerbations. Chest 1995; 108: 43S-52S.

131. Авдеев С.H., Шанина А.Г., Чучалин А.Г. Бактериальная инфекция у больных ХОБЛ с острой дыхательной недостаточностью. Клин. микробиол. антимикроб. химиотер. 2005; 7: 245-254.

132. Дворецкий Л.И., Дубровская Н.В., Грудинина С.А. и др. Левофлоксацин и макролиды при обострении хронического бронхита. Результаты длительного мониторинга больных. Инфекц. антимикроб. тер. 2005; 7.

133. van Zanten A.R., Oudijk M., Nohlmans-Paulssen M.K. et al. Continuous vs. intermittent cefotaxime administration in patients with chronic obstructive pulmonary disease and respiratory tract infections: pharmacokinetics/pharmacodynamics, bacterial susceptibility and clinical efficacy. British J Clin Pharmacol 2007; 63: 100-109.

134. Pfaller M.A., Ehrhardt A.F., Jones R.N. Frequency of pathogen occurrence and antimicrobial susceptibility among community-acquired respiratory tract infections in the respiratory surveillance program study: microbiology from the medical office practice environment. American J Med 2001; 111: Suppl 9A: 4S-12S; Discussion 36S-8S.

135. Miravitlles M., Espinosa C., Fernandez-Laso E. et al. Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Study Group of Bacterial Infection in COPD. Chest 1999; 116: 40-46.

136. Ram F.S., Rodriguez-Roisin R., Granados-Navarrete A. et al. Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane database of systematic reviews (Online) 2006:CD004403.

137. Reynolds A.Y. Chronic bronchitis and acute infectious exacerbations. In: Mandell G.L., Bennett J.E., Dolin R., eds. Principles and practice of infectious diseases. 5th ed. New York: Churchill Livingstone; 2000.

138. Roede B.M., Bresser P., El Moussaoui R. et al. Three vs. 10 days of amoxycillin-clavulanic acid for type 1 acute exacerbations of chronic obstructive pulmonary disease: a randomised, double-blind study. Clin Microbiol Infect 2007; 13: 284-290.

139. Sayiner A., Okyay N., Unsal I., Colpan N. Infective exacerbations of COPD. Chest 1999;115:1481.

140. Lode H., Allewelt M., Balk S. et al. A prediction model for bacterial etiology in acute exacerbations of COPD. Infection 2007; 35: 143-149.

141. Monso E., Garcia-Aymerich J., Soler N. et al. Bacterial infection in exacerbated COPD with changes in sputum characteristics. Epidemiol Infect 2003; 131: 799-804.

142. Grassi C., Salvatori E., Rosignoli M.T., Dionisio P. Randomized, doubleblind study of prulifloxacin versus ciprofloxacin in patients with acute exacerbations of chronic bronchitis. Respiration 2002; 69: 217-222.

143. Anzueto A., Niederman M.S., Tillotson G.S. Etiology, susceptibility, and treatment of acute bacterial exacerbations of complicated chronic bronchitis in the primary care setting: ciprofloxacin 750 mg b.i.d. versus clarithromycin 500 mg b.i.d. Bronchitis Study Group. Clin Ther 1998; 20: 885-900.

144. Anthonisen N.R., Manfreda J., Warren C.P. et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987; 106: 196-204.

145. Balter M.S., La Forge J., Low D.E. et al. Canadian guidelines for the management of acute exacerbations of chronic bronchitis. Can Respir J 2003; 10: Suppl B: 3B-32B.

146. Pauwels R.A., Buist A.S., Calverley P.M. et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop Summary. American J Respir Critic Car Med 2001; 163: 1256-1276.

147. Celli B.R., MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23: 932-946.

148. Ruiz-Gonzalez A., Gimenez A., Gomez-Arbones X. et al. Open-label, randomized comparison trial of long-term outcomes of levofloxacin versus standard antibiotic therapy in acute exacerbations of chronic obstructive pulmonary disease. Respirology (Carlton, Vic) 2007; 12: 117-121.

149. Dvoretskii L.I., Dubrovskaia N.V., Grudinina S.A. et al. Levofloxacin and macrolides in chronic bronchitis exacerbation: comparative analysis of the treatment efficacy and nonrelapsing periods. Antibiotiki i khimioter-apiia = Antibiotics and Chemoterapy [sic] 2007; 52: 21-31.

150. Grossman R.F., Ambrusz M.E., Fisher A.C. et al. Levofloxacin 750 mg QD for five days versus amoxicillin/clavulanate 875 mg/125 mg BID for ten days for treatment of acute bacterial exacerbation of chronic bronchitis: a post hoc analysis of data from severely ill patients. Clin Ther 2006; 28: 1175-1180.

151. Zuck P., Veyssier P., Brumpt I. Efficacy of levofloxacin in the treatment of acute exacerbation of chronic bronchitis in patients with risk factors. Rev Pneumol Cliniq 2004; 60: 269-277.

152. Martinez F.J., Grossman R.F., Zadeikis N. et al. Patient stratification in the management of acute bacterial exacerbation of chronic bronchitis: the role of levofloxacin 750 mg. Eur Respir J 2005; 25: 1001-1010.

153. Urueta-Robledo J., Ariza H., Jardim J.R. et al. Moxifloxacin versus levofloxacin against acute exacerbations of chronic bronchitis: the Latin American Cohort. Respitor Med 2006; 100: 1504-1511.

154. Canut A., Martin-Herrero J.E., Labora A., Maortua H. What are the most appropriate antibiotics for the treatment of acute exacerbation of chronic obstructive pulmonary disease? A therapeutic outcomes model. J Antimicrob Chemother 2007; 60: 605-612.

155. Khashab M.M., Xiang J., Kahn J.B. Comparison of the adverse event profiles of levofloxacin 500 mg and 750 mg in clinical trials for the treatment of respiratory infections. Curr Med Resrear Opin 2006; 22: 1997-2006.

156. Wilton L.V., Pearce G.L., Mann R.D. A comparison of ciprofloxacin, norfloxacin, ofloxacin, azithromycin and cefixime examined by observational cohort studies. British J Clin Pharmacol 1996; 41: 277-284.

157. van der Linden P.D., Sturkenboom M.C., Herings R.M. et al. Fluoroquinolones and risk of Achilles tendon disorders: case-control study. BMJ (Clinical research ed) 2002; 324: 1306-1307.

158. Makaryus A.N., Byrns K., Makaryus M.N. et al. Effect of ciprofloxacin and levofloxacin on the QT interval: is this a significant «clinical» event? Southern Med J 2006; 99: 52-56.

159. Morganroth J., Dimarco J.P., Anzueto A. et al. A randomized trial comparing the cardiac rhythm safety of moxifloxacin vs levofloxacin in elderly patients hospitalized with community-acquired pneumonia. Chest 2005; 128: 3398-3406.

160. Available from URL: http://romir.ru/news/res_results/405.html.

161. Pechere J.C., Hughes D., Kardas P., Cornaglia G. Non-compliance with antibiotic therapy for acute community infections: a global survey. Intern J Antimicrob Agents 2007; 29: 245-253.

162. Kardas P. Comparison of patient compliance with once-daily and twice-daily antibiotic regimens in respiratory tract infections: results of a randomized trial. J Antimicrob Chemother 2007; 59: 531-536.

163. Kardas P. Patient compliance with antibiotic treatment for respiratory tract infections. Ibid 2002; 49: 897-903.

164. Claxton A.J., Cramer J., Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001; 23: 1296-1310.


Для цитирования:


Гучев И.А., Мелехина Е.В., Юденич О.В. Левофлоксацин. Целесообразность высокодозовых режимов при инфекциях нижних дыхательных путей. Антибиотики и Химиотерапия. 2011;56(3-4):17-31.

For citation:


Guchev I.A., Melekhina E.V., Yudenich O.V. Levofloxacin. Expediency of High-Dose Regimens in Therapy of Lower Respiratory Tract Infections. Antibiotics and Chemotherapy. 2011;56(3-4):17-31. (In Russ.)

Просмотров: 27


ISSN 0235-2990 (Print)